Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/fusion-antibodies-plc">Fusion Antibodies</a> is a specialized Contract Research Organisation (CRO) focused on the high-growth antibody discovery and engineering market, offering services from discovery to stable cell line development.</li>
  <li>The company is currently in a turnaround phase, with FY2025 results showing a 73% revenue rebound from a weak FY2024, though it remains unprofitable with significant net losses and negative operating cash flow.</li>
  <li>Future prospects hinge on the successful commercialization of its new technology platforms, such as OptiMAL®, and securing intellectual property, which could provide a competitive edge and drive future growth in a competitive landscape.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Fusion Antibodies is a specialized Contract Research Organisation (CRO) focused on the high-growth antibody discovery and engineering market, offering services from discovery to stable cell line development.
  The company is currently in a turnaround phase, with FY2025 results showing a 73% revenue rebound from a weak FY2024, though it remains unprofitable with significant net losses and negative operating cash flow.
  Future prospects hinge on the successful commercialization of its new technology platforms, such as OptiMAL®, and securing intellectual property, which could provide a competitive edge and drive future growth in a competitive landscape.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Fusion Antibodies (FAB LN) - Aug 2026

Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

<ul>
<li>Beeks Financial Cloud Group 212.50p £136.67m (BKS.L) The cloud computing and connectivity provider for financial markets announced that it has secured a fiveyear software contract with an existing analytics customer for the deployment of Beeks Analytics and Market Edge Intelligence, with a total contract value (TCV) of $3.0m.</li>
<li>This brings the TCV of contracts secured in June 2026 to approx. $10m. T</li>
<li>he customer, a leading North American exchange operator, has expanded its deployment of Beeks Analytics and will also deploy Market Edge Intelligence in New York. Revenue recognition is expected to commence immediately.</li>
</ul>


Beeks Financial Cloud Group 212.50p £136.67m (BKS.L) The cloud computing and connectivity provider for financial markets announced that it has secured a fiveyear software contract with an existing analytics customer for the deployment of Beeks Analytics and Market Edge Intelligence, with a total contract value (TCV) of $3.0m.
This brings the TCV of contracts secured in June 2026 to approx. $10m. T
he customer, a leading North American exchange operator, has expanded its deployment of Beeks Analytics and will also deploy Market Edge Intelligence in New York. Revenue recognition is expected to commence immediately.


<ul><li>Friday Takeaway—delving a little deeper into UK small caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 30th January 2026 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication.</li><li>Top three shareholders are taken from the websites of the companies that we are writing about, unless there is a more up to date TR-1 notification RNS announcement.</li><li> These companies have global opportunities and are funded for accelerated growth FAB Transformational Platform QUBE Quantum Steps</li></ul>

Friday Takeaway—delving a little deeper into UK small caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 30th January 2026 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication.Top three shareholders are taken from the websites of the companies that we are writing about, unless there is a more up to date TR-1 notification RNS announcement. These companies have global opportunities and are funded for accelerated growth FAB Transformational Platform QUBE Quantum Steps

Fusion Antibodies Ltd - Friday Take Away: 30 January 2026

<ul>
<li>The technology-driven modular housing Company provided an operational market update outlining its geographic expansion strategy and technology roll-out.</li>
<li>The Company has completed the computerisation and integration of the entire modular housing production process, creating fully automated, high-precision housing manufacturing platforms.</li>
<li>At the heart of the system is the Company's proprietary Vertical Panel Casting Machine combined with Glass Fibre Reinforced Gypsum wall technology, a blend of advanced materials science, precision automation, and architectural flexibility. </li>
</ul>


The technology-driven modular housing Company provided an operational market update outlining its geographic expansion strategy and technology roll-out.
The Company has completed the computerisation and integration of the entire modular housing production process, creating fully automated, high-precision housing manufacturing platforms.
At the heart of the system is the Company's proprietary Vertical Panel Casting Machine combined with Glass Fibre Reinforced Gypsum wall technology, a blend of advanced materials science, precision automation, and architectural flexibility. 


Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Thematic (Sector/Industry)

<ul>
<li>The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.</li>
<li>Its main function is to highlight the attractions of life sciences investments over the long term.</li>
<li>After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025.</li>
</ul>


The Hardman &amp; Co Healthcare Index (HHI) has been running since 2009.
Its main function is to highlight the attractions of life sciences investments over the long term.
After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025.


Hardman & Co Healthcare Index: 2025 – Index rose, but another tough year

United Kingdom

Fusion Antibodies is a Collaborative Research Organisation (CRO) specializing in antibody discovery, engineering, and supply. The company offers a range of services including antibody generation, development, production, characterization, and optimization for therapeutic drug and diagnostic applications. Fusion Antibodies is headquartered in Belfast, United Kingdom, and was established in 2001.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fusion Antibodies (FAB LN)

Primer: Fusion Antibodies (FAB LN) - Aug 2026

Fusion Antibodies is a specialized Contract Research Organisation (CRO) focused on the high-growth antibody discovery and engineering market,...

αSK Primers

Hybridan Small Cap Feast: 15 June 2026

The cloud computing and connectivity provider for financial markets announced that it has secured a fiveyear software contract with an existing...

Hybridan

Fusion Antibodies Ltd - Friday Take Away: 30 January 2026

Friday Takeaway—delving a little deeper into UK small caps This will delve a little deeper on individual companies and focus on...

Hybridan

Hybridan Small Cap Feast: 16/10/2025

The technology-driven modular housing Company provided an operational market update outlining its geographic expansion strategy and technology roll...

Hybridan

Hardman & Co Healthcare Index: 2025 – Index rose, but another tough year

The Hardman & Co Healthcare Index (HHI) has been running since 2009.Its main function is to highlight the attractions of life sciences investments...

Hardman & Co

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)